TP53 and colorectal carcinoma: Losi et al. reported higher ITH in early CRC with respect to advanced stages in terms of TP53 and KRAS point mutations (70% vs. 20% and 60% vs. 20%, respectively), with an almost complete absence of heterogeneity in distant metastases.